8. Literatur


Aidoo M, McElroy PD, Koleczak MS, Terlouw DJ, ter Kuile FO, Nahlen B, Lal AA, Udhayakumar V. Tumor necrosis factor-alpha promoter variant 2 (TNF2) is associated with pre-term delivery, infant mortality, and malaria morbidity in western Kenya: Asembo Bay Cohort Project IX. *Genet Epidemiol* 2001; 21: 201-211.


Alonso PL, Lindsay SW, Armstrong Schellenberg JR, Gomez P, Hill AG, David PH, Fegan G, Cham K, Greenwood BM. A malaria control trial using insecticide-treated bed nets and targeted chemoprophylaxis in a rural area of The Gambia, west Africa. 2. Mortality and


Clark IA, Cowden WB. The pathophysiology of falciparum malaria. Pharmacol Therapeutics 2003; 99: 221-160.


Curtis J, Duraisingham MT, Trigg JK, Mbwana H, Warhurst DC, Curtis CF. Direct evidence that asparagine at position 108 of the Plasmodium falciparum dihydrofolate reductase is


Gamain B, Smith JD, Miller LH, Baruch DI. Modification in the CD36 binding domain of the Plasmodium falciparum variant antigen are responsible for the inability of chondroitin sulfate A adherent parasites to bind CD36. *Blood* 2001; 97: 3268-3274.


Maitland K, Williams TN, Newbold CI. *Plasmodium vivax* and *P. falciparum*: biological interactions and the possibility of cross-species immunity. *Parasitol Today* 1997; 13: 227


Murphy PM. Molecular mimicry and the generation of host defense protein diversity. *Cell* 1993; 72: 823-826.


Ofo-su-Okyere A, Mackinnon MJ, Sowa MP, Koram KA, Nkrumah F, Osei YD, Hill WG, Wilson MD, Arnot DE. Novel *Plasmodium falciparum* clones and rising clone multiplicities are associated with the increase in malaria morbidity in Ghanaian children during the transition into the high transmission season. *Parasitology* 2001; 123 (Pt. 2): 113-123.


Orjih AU. Increased accumulation of chloroquine and desethylchloroquine in homozygous sickle cells. *Bull World Health Organ* 1987; 65: 51-55.


Sergent E, Parrot L. L’immunité, la prémunition et la résistance innée. *Arch Inst Pasteur Algerie* 1945; 13: 279


